<!-- SPDX-License-Identifier: PolyForm-Noncommercial-1.0.0 -->

---
title: "Pro-Inflammatory Macrophages Suppress HIV Replication"
date: 2025-12-24
authors:
  - AI Whisperers
version: "0.1"
license: PolyForm-Noncommercial-1.0.0
---

# Pro-Inflammatory Macrophages Suppress HIV Replication

**ID:** PATH-006
**Year:** 2024
**Journal:** Frontiers in Immunology
**DOI:** [10.3389/fimmu.2024.1439328](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1439328/full)
**Institution:** University of Zurich

---

## Abstract

This 2024 study from the University of Zurich demonstrates that pro-inflammatory M1 macrophages suppress HIV replication both in humanized mice and ex vivo co-culture systems. Using myeloid cell depletion, cytokine analysis, and transcriptomic profiling, researchers show that macrophages upregulate interferon-stimulated genes (ISGs) and HIV co-receptor antagonists, providing mechanistic insights into natural antiviral immunity.

---

## Key Concepts

- **M1 Macrophages**: Pro-inflammatory, classically activated (IFN-γ polarized)
- **M2 Macrophages**: Anti-inflammatory, alternatively activated
- **ISGs**: Interferon-stimulated genes with antiviral activity
- **APOBEC3A/3G**: Restriction factors upregulated in M1 macrophages

---

## Study Design

### Experimental Approach
| Model | Purpose |
|:------|:--------|
| Humanized NSG mice | In vivo HIV replication dynamics |
| Myeloid cell depletion | Assess macrophage contribution |
| Ex vivo co-cultures | Dissect cellular mechanisms |
| Transcriptomics | Identify molecular pathways |

### Macrophage Polarization
| Phenotype | Stimuli | Characteristics |
|:----------|:--------|:----------------|
| M0 (resting) | None | Baseline state |
| M1 (pro-inflammatory) | IFN-γ + LPS | Anti-viral |
| M2 (anti-inflammatory) | IL-4/IL-13 | Pro-viral |

---

## Key Findings

### In Vivo Results
| Condition | HIV Replication |
|:----------|:----------------|
| Normal (macrophages present) | Controlled |
| **Myeloid cell depletion** | **Significant increase** |

> "Myeloid cell depletion resulted in a significant increase in HIV replication in humanized mice."

### Ex Vivo Permissiveness
| Macrophage Type | HIV Infection Rate |
|:----------------|:-------------------|
| M0 (resting) | 36.8% |
| M2 (anti-inflammatory) | 27.7% |
| **M1 (pro-inflammatory)** | **5.4%** |

> "M0 macrophages exhibited the highest permissiveness to cell-to-cell HIV-R5 infection (36.8 ± 18.6%), followed by M2 (27.7 ± 18.4%) and M1 (5.4 ± 3.8%)."

---

## Molecular Mechanisms

### ISG Upregulation
| Finding | Significance |
|:--------|:-------------|
| IFN-stimulated genes increased | Antiviral response |
| Co-receptor antagonists produced | Block HIV entry |
| APOBEC3A/3G upregulated | Hypermutation defense |

### APOBEC3 Restriction
| Effect | Mechanism |
|:-------|:----------|
| Viral DNA synthesis inhibition | APOBEC3A activity |
| Integration block | Restriction factor effect |
| Transcription reduction | Negative regulators |

> "IFNγ and TNFα stimulated M1 MDMs inhibited HIV-1 viral DNA synthesis, proviral integration, and transcription in comparison to unpolarized MDMs through an upregulation of APOBEC 3A in M1 MDMs."

---

## Phenotype Switching During Infection

### Temporal Dynamics
| Phase | Dominant Phenotype | Outcome |
|:------|:-------------------|:--------|
| Early infection | M1 (pro-inflammatory) | HIV suppression |
| TLR7 recognition | M1 transition | Immune activation |
| Late infection | M2 shift | HIV permissiveness |
| T cell recruitment | IL-4/IL-13 secretion | M2 polarization |

> "In the later stages of HIV-1 infection, there is a shift of macrophage phenotypes from the M1 pro-inflammatory to M2 anti-inflammatory phenotype due to the recruitment and activation of T cells."

---

## Co-Culture Experiments

### Experimental Setup
| Component | Details |
|:----------|:--------|
| HIV-infected PBMCs | Source of virus |
| Autologous MDMs | M0, M1, or M2 polarized |
| Readouts | Viral replication, cytokines |

### Results Summary
| Cytokine | M1 Effect | Antiviral Role |
|:---------|:----------|:---------------|
| IFN-γ | Produced | Restriction factor induction |
| TNF-α | Produced | Direct antiviral |
| IL-1β | Produced | Inflammatory response |

---

## Therapeutic Implications

### M1 Polarization as Strategy
| Approach | Rationale |
|:---------|:----------|
| TLR7/8 agonists | Promote M1 phenotype |
| IFN-γ augmentation | Enhance restriction |
| Prevent M2 shift | Maintain antiviral state |

### Cure Research Applications
| Application | Benefit |
|:------------|:--------|
| Reservoir targeting | M1 macrophages may clear infected cells |
| Latency reversal | Combined with M1 activation |
| Immune enhancement | Boost natural antiviral responses |

---

## Comparison: M1 vs M2 in HIV Context

| Feature | M1 (Pro-inflammatory) | M2 (Anti-inflammatory) |
|:--------|:----------------------|:-----------------------|
| HIV permissiveness | **Low (5.4%)** | High (27.7%) |
| ISG expression | High | Low |
| APOBEC3 levels | Elevated | Baseline |
| Cytokine profile | IFN-γ, TNF-α | IL-10, TGF-β |
| Therapeutic goal | **Promote** | Prevent |

---

## Relevance to Project

M1 macrophage research informs the Ternary VAE project:
- **Cell type restriction**: Sequence requirements for macrophage infection
- **APOBEC3 interactions**: Codon usage and hypermutation vulnerability
- **Immune evasion**: Sequences that evade M1-mediated restriction
- **Tropism determinants**: Macrophage vs T cell adaptation

---

*Added: 2025-12-24*
